Project Grant R15DK131507
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $378K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- This $551,696 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the cannabinoid 1 receptor (CB1R) in age-associated metabolic dysfunction-associated steatotic liver disease (MASLD). The research project, led by Oklahoma State University, seeks to determine how hepatic CB1R contributes to the exacerbation of MASLD...
- This federal Project Grant award from the U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative (AFRI) program provides $300,000.00 to Oklahoma State University (OSU) to conduct research on the role of the endocannabinoid system in the gut-liver axis and its impact on non-alcoholic fatty liver disease (NAFLD). The two-year project aims to identify molecules and mechanisms that contribute to NAFLD development via the gut-liver connection, with a focus on understanding...
- The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $169,388 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of California, Irvine (UCI). The purpose of this 5-year grant, awarded on September 9, 2025, is to explore the role of the enzyme fatty acid amide hydrolase (FAAH) and its regulation of endocannabinoid signaling as a novel, opiate-sparing therapeutic target for managing pain...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $2,999,512 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The University of Texas Southwestern Medical Center, doing business as Southwestern Medical School. This 4-year award, starting on September 1, 2025, will support research to investigate the regulation of mitochondrial health in mammalian livers, with a focus on understanding the...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $776,863 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Regents of the University of Michigan. The award will fund a multi-ancestry whole genome sequencing analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a globally prevalent condition caused by excess fat accumulation in the liver. The research aims to uncover...
- This Project Grant award of $144,950.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the expression, function, and immunomodulatory potential of endocannabinoid receptors, including TRPV2 and PPAR-A, as well as cannabidiol (CBD), in microglia in the context of HIV. The research goal is to investigate how the endocannabinoid system can modulate the HIV-induced inflammatory response in microglia, which is a key driver of...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the Department of Health and Human Services, awarded a $3,227,517 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Colorado-Denver. The grant, awarded on September 20, 2025 with a completion date of August 31, 2029, is funding research to investigate the effects of full-spectrum cannabidiol (CBD) on alcohol consumption and alcohol use disorder phenotypes. The goal is to identify safe and...